European stocks finished higher on Wednesday after a bumper day of earnings, while investors awaited news from a two-day policy meeting of the U.S. Federal Reserve.» Read More
European equities rallied on Thursday, closing nearly 1 percent higher as investors reacted to a raft of corporate earnings and fresh economic data.
New drugs and increased spending on research and development mean the "stars are aligned" for German drugs giant Bayer, the firm's CEO said.
Marijn Dekkers, CEO of Bayer, talks about the company's plans to separate themselves from their material science unit, saying they will focus on life sciences businesses going forward.
Marijn Dekkers, CEO of Bayer, says the company plans to increase its R&D budget this year, after strong earnings.
PARIS, Feb 20- Sanofi's new boss Olivier Brandicourt will earn up to 4.2 million euros a year at the drugs group and could pocket 4 million extra as a one-off golden handshake. The pay of the former medical doctor, who is due to take up his new role from April, was revealed in a statement by the French drugs firm on Friday, a day after the 59- year-old Bayer AG executive was...
TOKYO, Feb 20- German drugmaker Bayer AG is close to selling its diabetes devices business to KKR-backed Panasonic Healthcare Holdings Co Ltd and the unit could be valued at up to $2.3 billion, Bloomberg news reported. The announcement of the buyout may come as early as Friday, although the talks are ongoing and an agreement may be delayed or fall apart, Bloomberg...
PARIS, Feb 19- French drugmaker Sanofi on Thursday named Olivier Brandicourt, a Paris- educated doctor and head of Bayer AG's healthcare arm, as its chief executive officer. Brandicourt had been widely tipped to become Sanofi's new boss, a position that opened when Chris Viehbacher was suddenly sacked last year. "Olivier Brandicourt's strong experience...
Feb 10- Regeneron Pharmaceuticals Inc reported better-than-expected fourth-quarter sales, driven by surging demand for its blockbuster eye drug Eylea. The biotechnology company's net profit rose to $110.2 million, or 96 cents per share, in the fourth quarter ended Dec. 31 from $96.8 million, or 86 cents per share, a year earlier. Revenue, including...
Feb 10- Regeneron Pharmaceuticals Inc reported a nearly 14 percent jump in quarterly profit, driven by strong demand for its blockbuster eye drug Eylea. The biotechnology company's net profit rose to $110.2 million, or 96 cents per share, in the fourth quarter ended Dec. 31 from $96.8 million, or 86 cents per share, a year earlier. Revenue, including collaboration...
Merck reported earnings that beat analysts' expectations, but global sales dropped amid patent expirations and a drop in sales of its hep C drugs.
European shares closed higher on Thursday after an important announcement regarding the meetings of the European Central Bank.
Germany's largest drugmaker, Bayer, plans to float its plastics business on the stock market and focus on healthcare and crop science.
Marijn Dekkers,CEO of Bayer, says now is a "good time" to float the company's plastics business and prefers the IPO route.
Merck reported better-than-expected quarterly results, with sales of newer drugs mostly offsetting declining sales of drugs facing generic competition.
The way consumers would be informed when their food has been genetically engineered is being battled in Congress and among advocacy groups.
But Merck chief Kenneth Frazier also said the government needs to modify its high corporate tax code to level the playing field for American companies.
Some of the names on the move ahead of the open.
Which M&A deal represents the best value for shareholders?
Stocks fell Tuesday after American International Group reported a decline in profit.
Merck CEO Kenneth Frazier speaks with CNBC hours after announcing a blockbuster deal with Bayer.